We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.51B
1-Year Est. Return 164.17%
This Fund
S&P 500
This Quarter Est. Return
+59.12%
1 Year Est. Return
+164.17%
3 Year Est. Return
+929.47%
5 Year Est. Return
+823.75%
10 Year Est. Return
+18,826.17%
AUM
$8.26B
AUM Growth
+$2.81B
Cap. Flow
+$660M
Cap. Flow %
7.99%
Top 10 Hldgs %
46.78%
Holding
97
New
16
Increased
23
Reduced
35
Closed
10

Top Buys

Rank Stock Value
1
NVTA
Invitae Corporation
NVTA
+$242M
2
STTK icon
Shattuck Labs
STTK
+$181M
3
MDVL
MedAvail Holdings, Inc. Common Stock
MDVL
+$164M
4
ABBV icon
AbbVie
ABBV
+$133M
5
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$91.4M

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$275M
2
BNTX icon
BioNTech
BNTX
+$64.3M
3
BSX icon
Boston Scientific
BSX
+$54.3M
4
FOLD
Amicus Therapeutics
FOLD
+$50.2M
5
AXNX
Axonics, Inc. Common Stock
AXNX
+$37.8M

Sector Composition

Rank Sector Weight
1 Healthcare 95.01%
2 Technology 0.52%
3 Financials 0.46%
4 Consumer Staples 0.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APRE icon
76
Aprea Therapeutics
APRE
$8.79M
$6.24M 0.08%
63,436
-50,000
-44% -$23.8M
EAR
77
DELISTED
Eargo, Inc. Common Stock
EAR
$5.8M 0.07%
+6,474
New +$5.45M
DVAX
78
DELISTED
Dynavax Technologies
DVAX
$5.42M 0.07%
1,216,844
-1,331,776
-52% -$6.03M
MASS icon
79
908 Devices
MASS
$302M
$4.27M 0.05%
+75,000
New +$4.38M
OM icon
80
Outset Medical
OM
$77.9M
$3.98M 0.05%
4,667
– –
TCDA
81
DELISTED
Tricida, Inc. Common Stock
TCDA
$3.18M 0.04%
451,377
-2,407,038
-84% -$18.5M
RIGL icon
82
Rigel Pharmaceuticals
RIGL
$750M
$2.61M 0.03%
74,458
– –
SYRS
83
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$2.3M 0.03%
21,229
– –
VAPO
84
DELISTED
Vapotherm, Inc. Common Stock
VAPO
$672K 0.01%
3,125
– –
WVE icon
85
Wave Life Sciences
WVE
$1.12B
$622K 0.01%
79,018
-84,601
-52% -$710K
OVID icon
86
Ovid Therapeutics
OVID
$455M
$282K ﹤0.01%
121,950
– –
CSLT
87
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
$13K ﹤0.01%
10,229
– –
BSX icon
88
Boston Scientific
BSX
$65.4B
– –
-1,422,049
Closed -$54.3M
DXCM icon
89
DexCom
DXCM
$29.6B
– –
-333,648
Closed -$34.4M
GDRX icon
90
GoodRx Holdings
GDRX
$1.06B
– –
-200,000
Closed -$11.1M
IMVT icon
91
Immunovant
IMVT
$8.27B
– –
-120,940
Closed -$4.26M
AXNX
92
DELISTED
Axonics, Inc. Common Stock
AXNX
– –
-741,129
Closed -$37.8M
CBAY
93
DELISTED
Cymabay Therapeutics
CBAY
– –
-1,719,247
Closed -$12.4M
ODT
94
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
– –
-25,162
Closed -$338K
LMNX
95
DELISTED
Luminex Corp
LMNX
– –
-914,107
Closed -$24M
FSDC
96
DELISTED
FS Development Corp. Class A Common Stock
FSDC
– –
-1,000,000
Closed -$11.2M
IMMU
97
DELISTED
Immunomedics Inc
IMMU
– –
-3,234,934
Closed -$275M
1 2 3
4

Similar funds

ORI
Oak Ridge Investments Chicago, Illinois $1.51B AUM 37.25% 1-Year Est. Return
KP
Keel Point Huntsville, Alabama $1.51B AUM 20.06% 1-Year Est. Return
FMI
F/M Investments Washington, District of Columbia $1.51B AUM 25.86% 1-Year Est. Return
FCM
Fairholme Capital Management South Miami, Florida $1.51B AUM 28.27% 1-Year Est. Return
SCM
SG Capital Management Chicago, Illinois $1.51B AUM 49.98% 1-Year Est. Return
PP
PDS Planning Dublin, Ohio $1.52B AUM 18.08% 1-Year Est. Return
AM
Ares Management Los Angeles, California $1.52B AUM 12.97% 1-Year Est. Return
BFO
Boston Family Office Boston, Massachusetts $1.5B AUM 11.68% 1-Year Est. Return

Redmile Group's Q4 2020 Portfolio in Review

As of Q4 2020, Redmile Group held 97 positions worth $8.26B, up 52% from $5.45B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Redmile Group deployed $660M of net new capital in Q4 2020, opening 16 new positions and adding to 23 existing holdings. Its largest new stake was Shattuck Labs: 5,619,914 shares worth $295M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 93% a quarter earlier, followed by Technology and Financials.

On the sell side, the largest reduction was BioNTech, an estimated $64.3M trimmed.

  • Redmile Group's largest Q4 2020 buy was Shattuck Labs: 5,619,914 shares worth $295M.
  • Redmile Group added most to Invitae Corporation in Q4 2020, an estimated $242M increase.
  • Redmile Group's biggest Q4 2020 reduction was BioNTech, cutting an estimated $64.3M.
  • Redmile Group fully exited Immunomedics Inc in Q4 2020, selling an estimated $275M.
  • Redmile Group's ten largest holdings make up 47% of its $8.26B portfolio in Q4 2020.
  • Redmile Group opened 16 new positions and closed 10 in Q4 2020.
  • Redmile Group's portfolio value rose 52% quarter-over-quarter to $8.26B.

Based on Redmile Group's 13F filing for Q4 2020, filed 16 Feb 2021.